Literature DB >> 12878694

Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence.

Makoto Inoue1, Masayoshi Mishina, Hiroshi Ueda.   

Abstract

Tolerance and physical dependence caused by chronic treatment of narcotics are good models to study basic neuronal plasticity. Activation of the NMDA subtype of the glutamate receptor has been implicated as an anti-opioid system in the development of morphine analgesic tolerance and dependence. The present study examines the specific role of the epsilon1 subunit of the NMDA receptor using mice lacking the gene encoding epsilon1 subunit of the NMDA receptor (GluRepsilon1-/- mice). GluRepsilon1-/- mice showed significant enhancement and prolongation of morphine anti-nociception, compared with wild-type GluRepsilon1+/+ mice. GluRepsilon1-/- mice also showed a marked loss of the analgesic tolerance after repeated morphine treatments. In C57BL/6J mice treated with chronic morphine after tolerance paradigm, the GluRepsilon1 protein expression significantly increased in periaqueductal gray matter (PAG), ventral tegmental area (VTA) and nucleus accumbens (NAc), but not amygdala or hippocampus. The rescue of GluRepsilon1 protein by electroporation into the PAG and VTA, but not NAc of GluRepsilon1-/- mice significantly reversed morphine analgesic tolerance liability. Similar attempts were also performed in the naloxone-precipitated physical dependence paradigm. GluRepsilon1-/- mice showed marked loss of typical withdrawal abstinence behaviors, and significant enhancement of GluRepsilon1 protein expression was only observed in NAc by chronic morphine treatments after dependence paradigm. The rescue of GluRepsilon1 protein by electroporation into the NAc of GluRepsilon1-/- mice significantly reversed the loss of abstinence behaviors. These findings suggest that GluRepsilon1 has locus-specific roles in the development of morphine analgesic tolerance and physical dependence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878694      PMCID: PMC6740642     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  40 in total

1.  Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro.

Authors:  Ashish K Rehni; Nirmal Singh
Journal:  Psychopharmacology (Berl)       Date:  2011-09-20       Impact factor: 4.530

2.  The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Esther Berrocoso; Javier Garzón
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 3.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

4.  Modulation of histone deacetylase attenuates naloxone-precipitated opioid withdrawal syndrome.

Authors:  Ashish K Rehni; Nirmal Singh; Mahesh Rachamalla; Kulbhushan Tikoo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-25       Impact factor: 3.000

5.  Gentiopicroside attenuates morphine rewarding effect through downregulation of GluN2B receptors in nucleus accumbens.

Authors:  Shui-Bing Liu; Lan Ma; Hong-Ju Guo; Bin Feng; Yan-Yan Guo; Xiao-Qiang Li; Wen-Ji Sun; Lian-He Zheng; Ming-Gao Zhao
Journal:  CNS Neurosci Ther       Date:  2012-05-24       Impact factor: 5.243

6.  Essential role for RGS9 in opiate action.

Authors:  Venetia Zachariou; Dan Georgescu; Nick Sanchez; Zia Rahman; Ralph DiLeone; Olivier Berton; Rachael L Neve; Laura J Sim-Selley; Dana E Selley; Stephen J Gold; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

7.  Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors.

Authors:  Gad Klein; Aaron Juni; Caroline A Arout; Amanda R Waxman; Charles E Inturrisi; Benjamin Kest
Journal:  Eur J Pharmacol       Date:  2008-02-19       Impact factor: 4.432

8.  Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.

Authors:  Pilar Sánchez-Blázquez; María Rodríguez-Muñoz; Javier Garzón
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

9.  Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects.

Authors:  Bradford D Fischer; Sara J Ward; Fredrick E Henry; Linda A Dykstra
Journal:  Neuropharmacology       Date:  2009-08-21       Impact factor: 5.250

10.  Targeted mutation of EphB1 receptor prevents development of neuropathic hyperalgesia and physical dependence on morphine in mice.

Authors:  Yuan Han; Xue-Song Song; Wen-Tao Liu; Mark Henkemeyer; Xue-Jun Song
Journal:  Mol Pain       Date:  2008-11-21       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.